ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Biotechnology

Healthcare
$17.59 -0.60%

-$0.13 today

Market cap
$3.04B
Beta
0.83
P/E (TTM)
9.7
EPS (TTM)
$2.20
52W Low $19.69High $28.35

Volume 1.45M

Average 1.66M

Returns on capital

ACADIA Pharmaceuticals Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

31.9%

avg -35.2%

ROIC

8.1%

avg -37.0%

ROA

25.0%

avg -30.4%

Analysis

ROE is currently the strongest return metric at 31.9% versus its period average of -35.2%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Catherine E. Owen Adams

Chief Executive Officer & DirectorUSD 1.78M56——

Elizabeth Thompson

Executive Vice President and Head of Research & DevelopmentUSD 1.04M50——

Mark C. Schneyer

Executive Vice President & Chief Financial OfficerUSD 877.94K5271.32K0.04%

Jennifer J. Rhodes

Executive Vice President, Chief Legal Officer & SecretaryUSD 857.88K5611.28K<0.01%

Thomas Andrew Garner

Executive Vice President & Chief Commercial OfficerUSD 857.02K50——

Albert S. Kildani

Senior Vice President of Investor Relations & Corporate Communications————

Carl Segerstrom

Chief People Officer————

James K. Kihara

Senior Vice President of Finance—45——

Scott Cenci

Senior Vice President, Chief Information & Data Officer————

Allyson McMillan Youngblood

Senior Vice President of Rare Disease Franchise————

Konstantina Katcheves

Senior Vice President, Chief Business & Strategy Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 30, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

22

$2.46M

Net Transaction Value

−$2.46M

Net selling

Most Active

Schneyer Mark C.

9 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 30, 26

Schneyer Mark C.

Direct

Sell$69.3K
Aug 6, 26

Schneyer Mark C.

Direct

Sell$145K
Aug 6, 26

Schneyer Mark C.

Direct

Sell$272.6K
Aug 5, 26

Schneyer Mark C.

Direct

Sell$169.6K
Jul 30, 26

Thompson Elizabeth H.Z.

Direct

Sell$431.4K
Jul 30, 26

Thompson Elizabeth H.Z.

Direct

Sell$1.3K
Jun 26, 26

Kihara James

Direct

Sell$297.9K
May 26, 26

Kihara James

Direct

Sell$114.4K
May 4, 26

Schneyer Mark C.

Direct

Sell$76.4K
May 4, 26

Kihara James

Direct

Sell$29K

1–10 of 22

Summary

Insiders reported 0 buys worth $0.00 and 22 sells worth $2.46M over the last 12 months. That adds up to net selling of $2.46M. Schneyer Mark C. was the most active insider with 9 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
+1.3% (5yr)5 analysts
RevenueN/AN/A+27.5%
+11.2% (5yr)12 analysts
Net IncomeN/AN/AN/A
+1.3% (5yr)12 analysts
EBITN/AN/AN/A
+38.2% (5yr)12 analysts

Analysis

Recent growth has been strongest in Revenue at +27.5% over three years. Forward estimates point to EBIT at +38.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does ACADIA Pharmaceuticals Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ACAD's management, answered from reported figures.

Who manages ACAD?

ACADIA Pharmaceuticals Inc. (ACAD) lists 11 active executives. The top listed executive is Elizabeth Thompson, Executive Vice President and Head of Research & Development.

Are ACAD insiders buying or selling?

Recent insider activity shows net buying of $35.44M.